Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort
Fabrizia Gelardi(Vita-Salute San Raffaele University), Lidija Antunovic(Humanitas University), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Marcello Rodari(Humanitas University), Rita De Sanctis(Humanitas University), Alberto Zambelli, Roberta Zanca(Humanitas University), Martina Sollini(Humanitas University), Bethania Fernandes(Humanitas University), Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Testori(IRCCS Humanitas Research Hospital), Valentina Errico(IRCCS Humanitas Research Hospital), Arturo Chiti(Vita-Salute San Raffaele University), Armando Santoro(IRCCS Humanitas Research Hospital), Corrado Tinterri(Humanitas University), Andrea Sagona(IRCCS Humanitas Research Hospital)
Cited by 3
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532